髓母细胞瘤细胞在组织环境中的生长和扩增需要极光激酶 B。

IF 4.8 2区 医学 Q1 Biochemistry, Genetics and Molecular Biology Neoplasia Pub Date : 2024-11-08 DOI:10.1016/j.neo.2024.101078
Alexandre Gries , Karthiga Santhana Kumar , Fabien Kuttler , Özgün Özalp , Veronica Akle , Hanqing Zhang , Michael A. Grotzer , Stephan C.F. Neuhauss , Amin Allalou , Martin Baumgartner
{"title":"髓母细胞瘤细胞在组织环境中的生长和扩增需要极光激酶 B。","authors":"Alexandre Gries ,&nbsp;Karthiga Santhana Kumar ,&nbsp;Fabien Kuttler ,&nbsp;Özgün Özalp ,&nbsp;Veronica Akle ,&nbsp;Hanqing Zhang ,&nbsp;Michael A. Grotzer ,&nbsp;Stephan C.F. Neuhauss ,&nbsp;Amin Allalou ,&nbsp;Martin Baumgartner","doi":"10.1016/j.neo.2024.101078","DOIUrl":null,"url":null,"abstract":"<div><div>The impact of the tissue context on tumor growth and drug response in medulloblastoma (MB) is poorly understood. To gain insights into the growth and dissemination behavior of the MB tumor cells under treatment, we combined three-dimensional cell culture screening with <em>ex vivo</em> organotypic cerebellum slice co-culture (OCSC), which allowed the assessment of tumor cell behavior in the tissue context.</div><div>To identify druggable kinase pathways involved in invasion, we screened a panel of 274 kinase inhibitors and identified aurora kinase B (AURKB) as a potential anti-invasion drug target in MB. We validated tumor suppressive activities of the AURKB inhibitor (AURKBi) Barasertib (AZD1152-HQPA) and the structurally unrelated compound GSK-1070916 in cerebellum slice culture models for SHH, and Grp3 MB. Importantly, AURKBi are tumor suppressive in the tissue context, also in MB tumor cells that are <em>in vitro</em> resistant to the same treatment. We confirmed the requirement of AURKB for tumor growth and expansion in the tissue context through genetic suppression of AURKB by siRNA. We revealed that the combination of AURKBi with the SRC/BCR-ABL inhibitor Dasatinib acts synergistically to repress tumor growth and expansion in the highly invasive MB cell model ONS-76, but not in Grp3 MB cells. We demonstrate that tumor growth in the tissue context is suppressed by pharmacological inhibition of AURKB, comparable to the growth reduction observed after X-ray irradiation, which was used as the positive control. Finally, we show that exposure to µM concentrations of Barasertib does not cause developmental toxicity in fish larvae.</div><div>In conclusion, we demonstrate that AURKB is essential for MB tumor growth and expansion in the tissue context and the inhibition of AURKB is equally efficient as irradiation in repressing tumor cell growth. In patients younger than three years, pharmacological targeting of AURKB may thus constitute a novel means to overcome radiotherapy limitations.</div></div>","PeriodicalId":18917,"journal":{"name":"Neoplasia","volume":"59 ","pages":"Article 101078"},"PeriodicalIF":4.8000,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Aurora kinase B is required for growth and expansion of medulloblastoma cells in the tissue context\",\"authors\":\"Alexandre Gries ,&nbsp;Karthiga Santhana Kumar ,&nbsp;Fabien Kuttler ,&nbsp;Özgün Özalp ,&nbsp;Veronica Akle ,&nbsp;Hanqing Zhang ,&nbsp;Michael A. Grotzer ,&nbsp;Stephan C.F. Neuhauss ,&nbsp;Amin Allalou ,&nbsp;Martin Baumgartner\",\"doi\":\"10.1016/j.neo.2024.101078\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>The impact of the tissue context on tumor growth and drug response in medulloblastoma (MB) is poorly understood. To gain insights into the growth and dissemination behavior of the MB tumor cells under treatment, we combined three-dimensional cell culture screening with <em>ex vivo</em> organotypic cerebellum slice co-culture (OCSC), which allowed the assessment of tumor cell behavior in the tissue context.</div><div>To identify druggable kinase pathways involved in invasion, we screened a panel of 274 kinase inhibitors and identified aurora kinase B (AURKB) as a potential anti-invasion drug target in MB. We validated tumor suppressive activities of the AURKB inhibitor (AURKBi) Barasertib (AZD1152-HQPA) and the structurally unrelated compound GSK-1070916 in cerebellum slice culture models for SHH, and Grp3 MB. Importantly, AURKBi are tumor suppressive in the tissue context, also in MB tumor cells that are <em>in vitro</em> resistant to the same treatment. We confirmed the requirement of AURKB for tumor growth and expansion in the tissue context through genetic suppression of AURKB by siRNA. We revealed that the combination of AURKBi with the SRC/BCR-ABL inhibitor Dasatinib acts synergistically to repress tumor growth and expansion in the highly invasive MB cell model ONS-76, but not in Grp3 MB cells. We demonstrate that tumor growth in the tissue context is suppressed by pharmacological inhibition of AURKB, comparable to the growth reduction observed after X-ray irradiation, which was used as the positive control. Finally, we show that exposure to µM concentrations of Barasertib does not cause developmental toxicity in fish larvae.</div><div>In conclusion, we demonstrate that AURKB is essential for MB tumor growth and expansion in the tissue context and the inhibition of AURKB is equally efficient as irradiation in repressing tumor cell growth. In patients younger than three years, pharmacological targeting of AURKB may thus constitute a novel means to overcome radiotherapy limitations.</div></div>\",\"PeriodicalId\":18917,\"journal\":{\"name\":\"Neoplasia\",\"volume\":\"59 \",\"pages\":\"Article 101078\"},\"PeriodicalIF\":4.8000,\"publicationDate\":\"2024-11-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neoplasia\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1476558624001192\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"Biochemistry, Genetics and Molecular Biology\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neoplasia","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1476558624001192","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}
引用次数: 0

摘要

人们对髓母细胞瘤(MB)的组织环境对肿瘤生长和药物反应的影响知之甚少。为了深入了解接受治疗的髓母细胞瘤肿瘤细胞的生长和扩散行为,我们将三维细胞培养筛选与体外有机小脑切片共培养(OCSC)相结合,从而评估了肿瘤细胞在组织环境中的行为。为了确定参与侵袭的可药用激酶通路,我们筛选了274种激酶抑制剂,并确定极光激酶B(AURKB)是MB潜在的抗侵袭药物靶点。我们在小脑切片培养模型中验证了AURKB抑制剂(AURKBi)Barasertib(AZD1152-HQPA)和结构不相关的化合物GSK-1070916对SHH和Grp3 MB的抑瘤活性。重要的是,AURKBi 在组织环境中具有抑制肿瘤的作用,在体外对相同治疗具有抗药性的 MB 肿瘤细胞中也是如此。我们通过 siRNA 基因抑制 AURKB,证实了 AURKB 在组织环境中对肿瘤生长和扩张的要求。我们发现,在高侵袭性 MB 细胞模型 ONS-76 中,AURKBi 与 SRC/BCR-ABL 抑制剂达沙替尼联用可协同抑制肿瘤的生长和扩张,但在 Grp3 MB 细胞中则无效。我们证明,药理抑制 AURKB 可抑制组织中的肿瘤生长,与作为阳性对照的 X 射线照射后观察到的肿瘤生长减少效果相当。最后,我们还发现,暴露于 µM 浓度的巴拉塞替不会对鱼类幼体造成发育毒性。总之,我们证明了 AURKB 对 MB 肿瘤在组织环境中的生长和扩张至关重要,抑制 AURKB 与照射抑制肿瘤细胞生长的效果相同。因此,对于三岁以下的患者,以 AURKB 为药物靶点可能是克服放疗局限性的一种新方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Aurora kinase B is required for growth and expansion of medulloblastoma cells in the tissue context
The impact of the tissue context on tumor growth and drug response in medulloblastoma (MB) is poorly understood. To gain insights into the growth and dissemination behavior of the MB tumor cells under treatment, we combined three-dimensional cell culture screening with ex vivo organotypic cerebellum slice co-culture (OCSC), which allowed the assessment of tumor cell behavior in the tissue context.
To identify druggable kinase pathways involved in invasion, we screened a panel of 274 kinase inhibitors and identified aurora kinase B (AURKB) as a potential anti-invasion drug target in MB. We validated tumor suppressive activities of the AURKB inhibitor (AURKBi) Barasertib (AZD1152-HQPA) and the structurally unrelated compound GSK-1070916 in cerebellum slice culture models for SHH, and Grp3 MB. Importantly, AURKBi are tumor suppressive in the tissue context, also in MB tumor cells that are in vitro resistant to the same treatment. We confirmed the requirement of AURKB for tumor growth and expansion in the tissue context through genetic suppression of AURKB by siRNA. We revealed that the combination of AURKBi with the SRC/BCR-ABL inhibitor Dasatinib acts synergistically to repress tumor growth and expansion in the highly invasive MB cell model ONS-76, but not in Grp3 MB cells. We demonstrate that tumor growth in the tissue context is suppressed by pharmacological inhibition of AURKB, comparable to the growth reduction observed after X-ray irradiation, which was used as the positive control. Finally, we show that exposure to µM concentrations of Barasertib does not cause developmental toxicity in fish larvae.
In conclusion, we demonstrate that AURKB is essential for MB tumor growth and expansion in the tissue context and the inhibition of AURKB is equally efficient as irradiation in repressing tumor cell growth. In patients younger than three years, pharmacological targeting of AURKB may thus constitute a novel means to overcome radiotherapy limitations.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Neoplasia
Neoplasia 医学-肿瘤学
CiteScore
9.20
自引率
2.10%
发文量
82
审稿时长
26 days
期刊介绍: Neoplasia publishes the results of novel investigations in all areas of oncology research. The title Neoplasia was chosen to convey the journal’s breadth, which encompasses the traditional disciplines of cancer research as well as emerging fields and interdisciplinary investigations. Neoplasia is interested in studies describing new molecular and genetic findings relating to the neoplastic phenotype and in laboratory and clinical studies demonstrating creative applications of advances in the basic sciences to risk assessment, prognostic indications, detection, diagnosis, and treatment. In addition to regular Research Reports, Neoplasia also publishes Reviews and Meeting Reports. Neoplasia is committed to ensuring a thorough, fair, and rapid review and publication schedule to further its mission of serving both the scientific and clinical communities by disseminating important data and ideas in cancer research.
期刊最新文献
A novel regimen for pancreatic ductal adenocarcinoma targeting MEK, BCL-xL, and EGFR Depletion of β1,6-N-acetylglucosaminyltransferase reduces E-selectin binding capacity and migratory potential of human gastrointestinal adenocarcinoma cells A novel regulatory axis of MSI2-AGO2/miR-30a-3p-CGRRF1 drives cancer chemoresistance by upregulating the KRAS/ERK pathway Aurora kinase B is required for growth and expansion of medulloblastoma cells in the tissue context Cancer incidence and mortality among patients with new-onset atrial fibrillation: A population-based matched cohort study
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1